Base Pair Biotechnologies, Inc. is a world-leading provider of highly customized aptamer discovery and development services. The company was founded in 2012. It is privately held and located in the Houston, Texas metropolitan area, close to major medical centers and universities.
Mission Statement: Base Pair Biotechnologies seeks to make a lasting difference in the world – solving customer problems by creating novel affinity agents that empower healthcare solutions and protect our planet.
For more than a decade, Base Pair scientists have advanced aptamer development and selection through technical innovation and creative design. Base Pair scientists have led more than a dozen grant funded aptamer development projects and over one hundred and fifty customer funded projects. Base Pair has successfully developed aptamers used in a wide range of applications, including ELASA, fluorescence microscopy, fluorogenic solution-based assays, small molecule in vivo imaging, in vivo and in vitro biosensors, and lateral flow. Base Pair aptamers have been used for affinity resins and in scaffolds for three dimensional tissue culture/regeneration. “Base Pair is dedicated to problem-solving and innovation in the nucleic acid aptamer space.” – Bill Jackson, founder and Chief Scientist
Base Pair’s intellectual property portfolio includes more than two dozen issued and pending patents as well as trade secrets related to aptamer selection, aptamer screening, and aptamer sequences. Base Pair’s patented multiplex selection process reduces time and cost for aptamer discovery and facilitates development of specific- and pan-binders to related targets. Base Pair also has proprietary aptamer libraries that contain novel modifications, modulating binding properties and increasing conformational diversity. Base Pair has several proprietary techniques for developing aptamers to small molecules and uses novel methods for determining solution phase affinity. Base Pair has also developed proprietary methods for identifying aptamer sandwich pairs for ELASA and lateral flow methods.
We understand that aptamer discovery and development is a collaborative process. Every project begins with an in-depth technical discussion to fully understand customer needs. Our aptamer development scientists carefully consider the characteristics of the target(s), sample types, selectivity requirements, and downstream applications when designing, selecting, optimizing, and testing aptamers. Base Pair’s proprietary AptaTracker™ tool enables clients to closely monitor each stage of the aptamer development process. Base Pair scientists work closely with customers to develop aptamers with the highest likelihood of meeting performance requirements. Learn more about partnering with Base Pair.
Base Pair scientists work with researchers in a broad range of areas on projects varying widely in scope and complexity. From basic research projects involving single aptamers to diagnostic or therapeutic applications involving multiple aptamers to a family of proteins, Base Pair is committed to providing novel aptamer solutions. Base Pair offers a flexible business model ranging from the purchase of previously-developed aptamers (in small or large quantities), to custom aptamer and/or assay development, to exclusive licensing of specific aptamer sequences. “Through experience, technology, and collaboration, Base Pair Biotechnologies develops effective aptamers to address critical needs within the scientific community.” – Vicki Singer, CEO
Base Pair Values
Commitment: Each of us is committed to making a difference in the world, making it a better place for all of its inhabitants.
Value: Creating value for our customers, investors, employees and company is an essential part of everything we do.
Integrity: We uphold the highest standards of honesty and integrity in all of our actions.
Teamwork: We work together, across boundaries, to meet the needs of our customers and make a difference in the lives of people around the world.
Accountability: Each of us is personally accountable for our own actions and for delivering on the commitments made by ourselves and by the company.
Passion: We truly care about solving customer problems and employ the highest levels of intellectual curiosity, creativity and innovative thought to do so.
Vicki Singer, Ph.D. Chief Executive Officer
Dr. Singer has more than 25 years’ life science industry experience leading business segments, strategy, marketing, business development and research and development teams. She has served as Vice President and Head of Technology Strategy for Life Technologies (LIFE) and Thermo Fisher Scientific, as Global Head of Out Licensing for LIFE, Business Segment Director for the Labeling & Detection (Molecular Probes) business of Invitrogen, as Business Development Director for Invitrogen and Molecular Probes, and formed and led the Molecular Biology R&D team at Molecular Probes. Dr. Singer holds a Ph.D. in Biochemistry from UC Berkeley and performed postdoctoral studies at Harvard Medical School.
Bill Jackson, Ph.D. Founder and Chief Scientist
Dr. Jackson has served as Principal Investigator on over $5M in Small Business and Innovation Reseasrch grants. Dr. Jackson is also a recognized leader in the aptamer space having authored twelve peer-reviewed publications on aptamers as well as 50+ posters and conference proceedings. In 2010 he co-authored the first market research report on aptamers. Dr. Jackson is inventor on twelve issued U.S. patents (and many corresponding international filings) as well as numerous patents pending. Dr. Jackson holds a B.S. in biomedical engineering and a B.A. in Spanish literature from Texas A&M University and a Ph.D. in chemical engineering from the University of Houston.
Rob Batchelor, M.S. Director of Aptamer Development
Rob has more than 16 years of product and assay development and scientific team leadership experience. He led or participated in the development of more than fifty products while at Molecular Probes, Invitrogen, Life Technologies, and Marker Gene Technologies. He has extensive experience in the optimization of fluorescence-based assays. Rob received a B.S. in Biochemistry and an M.S. in Pharmacology from the University of Washington – Seattle.
Christopher Quan, Esq. General Counsel
Christopher has more than 12 years of experience working in intellectual property and legal segments in biotechnology, dental and engineering small companies with extensive work in patent prosecution, research and development practices and intellectual property licensing. Christopher holds a B.S. in biomedical engineering from the University of Rochester and a J.D. from the University of Houston. He is a registered U.S. patent attorney and is admitted to the bar in Texas.
The company also has a highly qualified network of technical expert consultants, including chemists, biologists, and engineers.